FR167653, a potent suppressant of interleukin‐1 and tumor necrosis factor‐<b>α</b> production, ameliorates colonic lesions in experimentally induced acute colitis<b>¹</b>

Abstract

Subcutaneous administration of FR167653 was able to ameliorate the acute changes induced by acetic acid instillation in a dose-dependent manner. This is the first report to evaluate the dual inhibition of the production of IL-1 and TNF-alpha, offered by FR167653, in acute experimental colitis. Further studies are necessary to evaluate FR167653's efficacy and safety on long-term conditions.